HEPATOSTAT : EVALUATION DE L'EFFICACITE ET LA TOLERANCE DE LA BITHERAPIE CHEZ LES PATIENTS MAROCAINS TRAITES DE L'HEPATITE C - Archive ouverte HAL Access content directly
Conference Papers Year :

HEPATOSTAT : EVALUATION DE L'EFFICACITE ET LA TOLERANCE DE LA BITHERAPIE CHEZ LES PATIENTS MAROCAINS TRAITES DE L'HEPATITE C

(1) , (1)
1

Abstract

Title: Evaluation of the efficacy and safety of bitherapy on Moroccan patients treated from hepatitis C. Dr ghassan Elmalki 1, Pr Samir Ahid 1, and Pr Yahia Cherrahn1 1 Research Team of Pharmacoepidemiology & Pharmacoeconomics. Laboratory of Pharmacology - Toxicology, Faculty of Medecine and Pharmacy, Rabat, Rabat, Morocco. Background: In Morocco studies estimate a prevalence of HCV to 3,5% for the whole population, and 5% for the age group between 45 and 75 years. According to these results, the number of patients with HCV in Morocco reached 300 000 and only 15 000 patients treated. Objectives: The aim of this work is to findout the efficacy and safety of treatment with interferon alfa-2a and ribavirin in Moroccan patients suffrring from hepatitis C and identify factors associated with treatment response. Methods: This is a retrospective study conducted between February and August 2012 in the regions of Casablanca, El Jadida, Mohammedia, Khouribgua, Beni Mellal, Safi; concerning clinical, paraclinical and therapeutic data collected from patients suffering from hepatitis C and treated over a period of 24 weeks (genotype 2, 3, 4) or 48 weeks (genotype 1). Results: At the end of the study, 143 patients were followed up. The average age was 58.1 years. The sex ratio M / F was 0.90. Genotype 1 was observed in 63 patients (43.4%), genotype 2 in 59 patients (41.3%). The positive response was observed in 73 patients (51.4), relapse in 42 patients (29.4%) and negative response in 28 patients (19.5%). 14 patients stopped their treatment (9.8%). The main side effects were asthenia (88.8%), metabolic and liver complications : the hepatocellular carcinoma, cirrhosis, graft cases, leukopenia, acute anemia (4.9%). In multivariate analysis, the associated factor with healing was discontinuation of treatment (p = 0.005 OR = 12.2 95% CI [-60.705 2.482]. Predictive Values of a Positive Response at week 12 were : 83, 01% for genotype 1 and 95% for genotype 2. Predictive Values of Negative Response at week 12 were : 59.25% for genotype 1 and 33.33% for genotype 2. Conclusions: Discontinuations constitute a significant risk to the success of the treatment, improving treatment outcomes of hepatitis C depends on the continuity of the treatment itself, compliance with protocols and patient education.
Fichier principal
Vignette du fichier
abstract_soumission_fevrier_2013.pdf (115.99 Ko) Télécharger le fichier
Vignette du fichier
hepatostat_3cnpee_presentation_11_Mai_2013.pptx (1.02 Mo) Télécharger le fichier
Origin : Files produced by the author(s)
Format : Other

Dates and versions

hal-00831287 , version 1 (06-06-2013)

Identifiers

  • HAL Id : hal-00831287 , version 1

Cite

Ghassan El Malki, Samir Ahid. HEPATOSTAT : EVALUATION DE L'EFFICACITE ET LA TOLERANCE DE LA BITHERAPIE CHEZ LES PATIENTS MAROCAINS TRAITES DE L'HEPATITE C. pharmacoépidémiologie et exigences réglementaires., May 2013, Rabat, Maroc. ⟨hal-00831287⟩

Collections

CONFREMO
182 View
72 Download

Share

Gmail Facebook Twitter LinkedIn More